Why Vincerx Pharma (VINC) Stock Is Falling

Vincerx Pharma Inc VINC shares are trading lower by 9.7% to $0.81 during Friday’s session after the company priced an underwritten public offering, including 6 million shares of common stock with accompanying warrants to purchase the same number of shares, and pre-funded warrants for up to 16 million shares with accompanying warrants for the same amount.

The combined public offering price for each share and accompanying warrant is $0.75, and for each pre-funded warrant and accompanying warrant, it is $0.7499. The pre-funded warrants have an exercise price of $0.0001 per share and can be exercised immediately until fully exercised, while the common stock warrants have an exercise price of $1.00 per share and expire five years from the date of issuance.

The offering is expected to raise approximately $16.5 million for Vincerx before expenses and is set to close around April 30, pending customary closing conditions. Leerink Partners is the sole bookrunning manager for the offering.

See Also: Dan Ives Says AI Is The ‘Fourth Industrial Revolution’ After ‘Robust’ Results From Microsoft And Google: ‘1995 Moment’

Should I Sell My VINC Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of Vincerx Pharma have lost 38.13% year to date. This compares to the average annual return of -62.46%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Vincerx Pharma stock currently has an RSI of 42.77, indicating neutral conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

SOFI has a 52-week high of $9.37 and a 52-week low of $0.61.